

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

This announcement, for which the directors (the “Directors”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People’s Republic of China (the “PRC”))
(Stock code: 8329)

CLARIFICATION ANNOUNCEMENT

The board of directors (the “Board”) of the Company makes this clarification announcement in response to a press article published in the People’s Republic of China (the “PRC”) on 11 June 2009 (the “Press Article”) regarding, among other things, the entry by the Company of a cooperation arrangement with the State Key Laboratory of Emerging Infectious Diseases of the University of Hong Kong (which is headed by Professor Guan Yi) (the “State Key Laboratory”) and the commencement of the research, development and production of Type A H1N1 influenza vaccines.

The Board wishes to clarify certain matters reported in the Press Article, as follows:

- (1) the Company is currently in negotiations with the State Key Laboratory on their cooperation arrangement with respect to (i) the joint research and development of influenza virus mutation and strains for vaccine production and (ii) the related project application to be made jointly by the parties to the PRC government authorities (the “Cooperation Arrangement”). However, no legally binding agreement in respect of the Cooperation Arrangement has been executed by the Company and the State Key Laboratory as at the date of this announcement.

(2) The Company has not carried out any production of Type A H1N1 influenza vaccines but has started the preparation work for the production of Type A H1N1 influenza vaccines as at the date of this announcement. The Company is applying for the virus strain for the production of Type A H1N1 influenza vaccine. It is expected the virus strain for the production of Type A H1N1 influenza vaccine will be available next week. The Company has also carried out the upgrading work on the existing vaccines production workshop with a production capacity of one million doses. After the improved production workshop passes the GMP certification, the Company will commence the production of Type A H1N1 influenza vaccine. It is anticipated that the production capacity will be in the range of one million to two million doses. The Company currently has no plan to produce Type A H1N1 influenza vaccine at its vaccines production base with a production capacity of 10 million doses.

As the Cooperation Arrangement is still under negotiations and no legally binding agreement has been executed by the Company and the State Key Laboratory, the Cooperation Arrangement may or may not proceed. Shareholders and investors of the Company should exercise caution when dealing in the H shares of the Company.

Further announcement will be made by the Company on the Cooperation Arrangement as and when appropriate.

On behalf of the Board
Shenzhen Neptunus Interlong Bio-Technique Company Limited
Zhang Si Min
Chairman

Shenzhen, the PRC, 12 June 2009

As at the date of this announcement, the executive Directors are Mr. Zhang Si Min and Mr. Chai Xiang Dong; the non-executive Directors are Mr. Ren De Quan and Ms. Yu Lin; and the independent non-executive Directors are Mr. Lu Sun, Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at <http://www.hkgem.com> for at least 7 days from its date of publication and on the website of the Company at www.interlong.com.

** For identification purpose only*